Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability

Maytansine and its analogues (maytansinoids) are potent microtubule-targeted compounds that inhibit proliferation of cells at mitosis. Antibody-maytansinoid conjugates consisting of maytansinoids (DM1 and DM4) attached to tumor-specific antibodies have shown promising clinical results. To determine the mechanism by which the antibody-DM1 conjugates inhibit cell proliferation, we examined the effects of the cleavable anti-EpCAM-SPP-DM1 and uncleavable anti-EpCAM-SMCC-DM1 conjugates on MCF7 human breast tumor cells. We also examined the effects of the free maytansinoids, maytansine and S-methyl DM1 (a version of DM1 that is stable in cell culture medium), for comparison. Both the conjugates and free maytansinoids potently inhibited MCF7 cell proliferation at nanomolar and subnanomolar concentrations, respectively, by arresting the cells in mitotic prometaphase/metaphase. Arrest occurred in concert with the internalization and intracellular processing of both conjugates under conditions that induced abnormal spindle organization and suppressed microtubule dynamic instability. Microtubule depolymerization occurred only at significantly higher drug concentrations. The results indicate that free maytansinoids, antibody-maytansinoid conjugates, and their metabolites exert their potent antimitotic effects through a common mechanism involving suppression of microtubule dynamic instability. Mol Cancer Ther; 9(10); 2700–13. ©2010 AACR.

[1]  Jordan Ma,et al.  Mechanism of action of antitumor drugs that interact with microtubules and tubulin. , 2012 .

[2]  E. Oroudjev,et al.  Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules , 2010, Molecular Cancer Therapeutics.

[3]  Suzanne F. Jones,et al.  Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. K. Maloney,et al.  Antibody-maytansinoid conjugates designed to bypass multidrug resistance. , 2010, Cancer Research.

[5]  K. Singletary,et al.  Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane. , 2008, Carcinogenesis.

[6]  Franck Perez,et al.  Detection of GTP-Tubulin Conformation in Vivo Reveals a Role for GTP Remnants in Microtubule Rescues , 2008, Science.

[7]  John M Lambert,et al.  Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.

[8]  R. Chari.  Targeted cancer therapy: conferring specificity to cytotoxic drugs. , 2008, Accounts of chemical research.

[9]  M. Jordan,et al.  How do microtubule-targeted drugs work? An overview. , 2007, Current cancer drug targets.

[10]  V. Goldmacher,et al.  Cell killing by antibody-drug conjugates. , 2007, Cancer letters.

[11]  A. Tolcher,et al.  Technology Insight: cytotoxic drug immunoconjugates for cancer therapy , 2007, Nature Clinical Practice Oncology.

[12]  Alexander Staab,et al.  A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus , 2006, Clinical Cancer Research.

[13]  G. Larson,et al.  2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules , 2006, Molecular Cancer Therapeutics.

[14]  Yelena Kovtun,et al.  Semisynthetic maytansine analogues for the targeted treatment of cancer. , 2006, Journal of medicinal chemistry.

[15]  R. Lutz,et al.  Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. , 2006, Cancer research.

[16]  T. Chittenden,et al.  Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. , 2006, Cancer research.

[17]  J. Lambert.  Drug-conjugated monoclonal antibodies for the treatment of cancer. , 2005, Current opinion in pharmacology.

[18]  Anna M Wu,et al.  Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.

[19]  Suzanne V. Smith.  Technology evaluation: huN901-DM1, ImmunoGen. , 2005, Current opinion in molecular therapeutics.

[20]  R. Schilsky,et al.  A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors , 2004, Clinical Cancer Research.

[21]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[22]  Hongsheng Xie,et al.  Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice , 2004, Journal of Pharmacology and Experimental Therapeutics.

[23]  M. Jordan,et al.  Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. , 2003, Cancer research.

[24]  A. Tolcher,et al.  Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Rebhun,et al.  Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids. , 2002, Journal of medicinal chemistry.

[26]  B. Hill,et al.  Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. , 2001, Molecular pharmacology.

[27]  N. Kedersha,et al.  Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Jordan,et al.  Mechanism of inhibition of cell proliferation by Vinca alkaloids. , 1991, Cancer research.

[29]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[30]  A. B. Huang,et al.  Maytansine inhibits nucleotide binding at the exchangeable site of tubulin. , 1985, Biochemical and biophysical research communications.

[31]  A. Verma,et al.  The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides. , 1977, The Journal of organic chemistry.

[32]  B. Bhattacharyya,et al.  Maytansine binding to the vinblastine sites of tubulin , 1977, FEBS letters.

[33]  D. Johns,et al.  Binding of maytansine to rat brain tubulin. , 1976, Biochemical and biophysical research communications.

[34]  Adamson Rh,et al.  Pharmacology of antitumor agents from higher plants. , 1976 .

[35]  R. Adamson,et al.  Experimental studies with maytansine--a new antitumor agent. , 1976, Bibliotheca haematologica.

[36]  G A Howie,et al.  Antimitotic activity of the potent tumor inhibitor maytansine. , 1975, Science.

[37]  R. L. Dion,et al.  Initial studies on maytansine-induced metaphase arrest in L1210 murine leukemia cells. , 1975, Biochemical pharmacology.

[38]  C. Gilmore,et al.  Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. , 1972, Journal of the American Chemical Society.

[39]  E. Oroudjev,et al.  Determination of microtubule dynamic instability in living cells. , 2010, Methods in cell biology.

[40]  Rajeeva Singh,et al.  Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. , 2010, Bioconjugate chemistry.

[41]  M. Jordan,et al.  Mechanism of action of antitumor drugs that interact with microtubules and tubulin. , 2002, Current medicinal chemistry. Anti-cancer agents.

[42]  M. Jordan,et al.  The use and action of drugs in analyzing mitosis. , 1999, Methods in cell biology.

[43]  M. Jordan,et al.  Use of drugs to study role of microtubule assembly dynamics in living cells. , 1998, Methods in enzymology.

[44]  S. Shah,et al.  Immunoconjugates containing novel maytansinoids: promising anticancer drugs. , 1992, Cancer research.

[45]  R. Adamson,et al.  Pharmacology of antitumor agents from higher plants. , 1976, Cancer treatment reports.